Progyny, Inc.

PGNY

US74340E1038

Managed Healthcare

Real-time Estimate Cboe BZX Other stock markets 01:42:25 2026-01-21 pm EST			5-day change	1st Jan Change
25.28 ^USD	-0.37%		-2.90%	-1.24%

Jan. 13	Progyny, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 07:30 AM
Jan. 12	Progyny to discuss updated financial expectations at upcoming JP Morgan healthcare conference	RE

Progyny Shares Rise After CEO Anevski Buys $1.9 Million Worth of Shares

Published on 11/17/2025 at 11:58 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Progyny, Inc.

Jan. 13	Progyny, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 07:30 AM
Jan. 12	Progyny to discuss updated financial expectations at upcoming JP Morgan healthcare conference	RE
Jan. 12	Progyny Inc anticipates Q4 and full year results to be slightly above previously provided financial guidance	RE
Dec. 17	Progyny, Inc. Announces Cessation of Michael Sturmer as President, Effective as of December 31, 2025	CI
Nov. 19	Progyny Insider Sold Shares Worth $543,227, According to a Recent SEC Filing	MT
Nov. 17	Progyny Shares Rise After CEO Anevski Buys $1.9 Million Worth of Shares	MT
Nov. 17	Progyny Insider Bought Shares Worth $1,930,896, According to a Recent SEC Filing	MT
Nov. 12	Progyny Shares Rise After KeyBanc Upgrade	MT
Nov. 12	KeyBanc Upgrades Progyny to Overweight From Sector Weight, Sets $30 Price Target	MT
Nov. 11	Truist Raises Price Target on Progyny to $28 From $27, Keeps Hold Rating	MT
Nov. 06	Progyny, Inc., Q3 2025 Earnings Call, Nov 06, 2025
Nov. 06	Progyny Q3 revenue beats expectations on robust member engagement, authorises $200 mln share buyback	RE
Nov. 06	Progyny, Inc. announces an Equity Buyback for $200 million worth of its shares.	CI
Nov. 06	Earnings Flash (PGNY) Progyny, Inc. Reports Q3 Revenue $313.3M, vs. FactSet Est of $299.3M	MT
Nov. 06	(PGNY) Progyny, Inc. Expects Q4 Adjusted EPS Range $0.37 - $0.40	MT
Nov. 06	(PGNY) Progyny, Inc. Expects Q4 Revenue Range $292.7M - $307.7M	MT
Nov. 06	Earnings Flash (PGNY) Progyny, Inc. Posts Q3 Adjusted EPS $0.45 per Share, vs. FactSet Est of $0.39	MT
Nov. 06	Progyny, Inc. Updates Earnings Guidance for the Year Ending December 31, 2025	CI
Nov. 06	Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2025	CI
Nov. 06	Progyny, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 05	Progyny, Inc. authorizes a Buyback Plan.	CI
25-10-07	Alert tagged to Progyny withdrawn	RE
25-09-10	Fellow Health Joins Progyny Network to Support Men's Health Fertility Screening with Mail-In Semen Analysis for Fertility Care	CI
25-09-01	Progyny integrates OURA's wearable insights
25-08-08	Progyny's Q2 Adjusted Earnings, Revenue Increase; 2025 Outlook Raised	MT

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Employees

678

Sector

Managed Healthcare

Calendar

Mar. 01 - Q4 2025 Earnings Release (Projected)

More about the company